Caldera Therapeutics erupts with $112.5M and a China-originated IBD bispecific
Caldera Therapeutics携1.125亿美元融资与一款源自manbetx3.0 的IBD双特异性疗法“喷发”出场

After selling Morphic Therapeutic to Eli Lilly for $3.2 billion, Praveen Tipirneni is back a year and a half later with a new biotech working in Morphic’s old wheelhouse of inflammatory bowel disease.
将 Morphic Therapeutic 以32亿美元出售给礼来后，普拉文•蒂皮尔涅尼在一年半后卷土重来，创立了一家在炎症性肠病这一 Morphic 旧有领域深耕的新生物科技公司。